It is intended to use the product obtained from the blood of the cow to perform blood transfusions in people. The U.S. FDA (Food and Drug Administration) has authorized Biopure to conduct tests that its product does not cause damage. Main advantages, better blood control and compatibility between donor and recipient (belonging to the same blood group, etc.) would be abandonment. Clinical trials are expected to begin in Europe later this year.